SCHEMBL13283197

SCHEMBL13283197

CCNc1ccc(NC2=C(N3CCCCC3)C(=O)c3ccccc3C2=O)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ APAF1 O14727 14/20 0.74
▸ NPC1 O15118 4/20 0.74
▸ RAB9A P51151 3/20 0.74
▸ MAPT P10636 11/20 0.73
▸ ALDH1A1 P00352 9/20 0.73
▸ SMN1; SMN2 Q16637 6/20 0.73
▸ POLB P06746 6/20 0.73
▸ HTT P42858 5/20 0.73
▸ MITF O75030 5/20 0.73
▸ LMNA P02545 4/20 0.73
▸ KLF5 Q13887 1/20 0.73
▸ CDC25A P30304 1/20 0.65
▸ CDC25B P30305 1/20 0.65
▸ L3MBTL1 Q9Y468 5/20 0.59
▸ MEN1 O00255 4/20 0.59
▸ KMT2A Q03164 4/20 0.59
▸ GAA P10253 3/20 0.59
▸ NPSR1 Q6W5P4 3/20 0.59
▸ NSD2 O96028 3/20 0.59
▸ MAPK1 P28482 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10446575 0.88 APAF1 (0.65) APAF1NPC1RAB9AMAPTALDH1A1
SCHEMBL5807881 0.85 APAF1 (1.00) APAF1NPC1RAB9AMAPTALDH1A1
SCHEMBL16297187 0.85 APAF1 (1.00) APAF1NPC1RAB9AMAPTALDH1A1
SCHEMBL4874221 0.84 APAF1 (0.97) APAF1NPC1RAB9AMAPTALDH1A1
SCHEMBL7247303 0.83 MAPT (0.97) APAF1NPC1RAB9AMAPTALDH1A1
SCHEMBL16296652 0.83 MAPT (0.79) APAF1NPC1RAB9AMAPTALDH1A1
SCHEMBL16296848 0.83 APAF1 (0.79) APAF1NPC1RAB9AMAPTALDH1A1
SCHEMBL16296847 0.83 APAF1 (0.79) APAF1NPC1RAB9AMAPTALDH1A1
SCHEMBL16296946 0.83 MAPT (0.79) APAF1NPC1RAB9AMAPTALDH1A1
SCHEMBL16297222 0.82 APAF1 (0.74) APAF1NPC1RAB9AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190807-A1 CDKI Pathway inhibitors and uses thereof to regulate expression to TAU protein SENEX BIOTECHNOLOGY, INC. 2010-07-29 — — US disclosed
US-20090281129-A1 CDKI PATHWAY INHIBITORS AND USES THEREOF SENEX BIOTECHNOLOGY, INC. 2009-11-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190807-A1 CDKI Pathway inhibitors and uses thereof to regulate expression to TAU protein MAPT, CDK5, CDKN1A APAF1 1795/4885NPC1 3013/4885RAB9A 2580/4885
US-20090281129-A1 CDKI PATHWAY INHIBITORS AND USES THEREOF CDKN1A, CDK6, CCNI APAF1 716/4885NPC1 2846/4885RAB9A 2584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback